# US 2021/0277065 A1 · Compositions comprising hiv envelopes to induce ch235 lineage antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277065 A1
- Document ID: US20210277065A1
- Status: Published application
- Kind: A1
- Application number: 17/199,319
- Filed: 2021-03-11
- Published: 2021-09-09
- Earliest claimed: 2016-03-01
- Assignees: Duke University; Los Alamos National Security, LLC
- Applicants: Duke University; Los Alamos National Security, LLC
- Inventors: Barton F. HAYNES; Mattia BONSIGNORI; Hua-Xin LIAO; Bette T. KORBER; Peter T. HRABER; Kevin O. SAUNDERS
- Web page: https://patentgrep.com/patent/US20210277065A1

## CPC

- C07K 14/005: from viruses
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelope selections from individual CH505, and methods for swarm immunizations using combinations of HIV-1 envelopes.

## Claims

### Claim at position 1

-19. (canceled)

### Claim 20

A nucleic acid encoding a recombinant HIV-1 envelope polypeptide comprising all the consecutive amino acids after the signal peptide in HIV-1 envelope CH505TFchim.6R.SOSIP.664v4.1 (SEQ ID NO:260), CH505M5chim.6R.SOSIP.664v4.1 (SEQ ID NO:242), CH505M11chim.6R.SOSIP.664v4.1 (SEQ ID NO:244), CH505w20.14chim.6R.SOSIP.664v4.1 (SEQ ID NO:254), CH505w30.20.chim.6R.SOSIP.664v4.1 (SEQ ID NO:258), CH505w30.12chim.6R.SOSIP.664v4.1 (SEQ ID NO:256), or CH505w136.B18chim.6R.SOSIP.664v4.1 (SEQ ID NO:252).

### Claim 21 (depends on 20)

The nucleic acid of claim 20, wherein the nucleic acid encodes a recombinant HIV-1 envelope polypeptide comprising all the consecutive amino acids after the signal peptide in HIV-1 envelope CH505TFchim.6R.SOSIP.664v4.1 (SEQ ID NO:260).

### Claim 22 (depends on 20)

An immunogenic composition comprising the nucleic acid of claim 20 and a carrier.

### Claim 23 (depends on 22)

The immunogenic composition of claim 22, further comprising an adjuvant.

### Claim 24 (depends on 21)

An immunogenic composition comprising the nucleic acid of claim 21 and a carrier.

### Claim 25 (depends on 24)

The immunogenic composition of claim 24, further comprising an adjuvant.

### Claim 26 (depends on 20)

The nucleic acid of claim 20, wherein the nucleic acid is operably linked to a promoter inserted in an expression vector.

### Claim 27 (depends on 21)

The nucleic acid of claim 21, wherein the nucleic acid is operably linked to a promoter inserted in an expression vector.

### Claim 28 (depends on 22)

The immunogenic composition of claim 22, wherein the nucleic acid is operably linked to a promoter inserted in an expression vector.

### Claim 29 (depends on 24)

The immunogenic composition of claim 24, wherein the nucleic acid is operably linked to a promoter inserted in an expression vector.

### Claim 30

A method of inducing an immune response in a subject comprising administering a composition comprising a nucleic acid encoding a recombinant HIV-1 envelope polypeptide comprising all the consecutive amino acids after the signal peptide in HIV-1 envelope CH505TFchim.6R.SOSIP.664v4.1 (SEQ ID NO:260), CH505M5chim.6R.SOSIP.664v4.1 (SEQ ID NO:242), CH505M11chim.6R.SOSIP.664v4.1 (SEQ ID NO:244), CH505w20.14chim.6R.SOSIP.664v4.1 (SEQ ID NO:254), CH505w30.20.chim.6R.SOSIP.664v4.1 (SEQ ID NO:258), CH505w30.12chim.6R.SOSIP.664v4.1 (SEQ ID NO:256), or CH505w136.B18chim.6R.SOSIP.664v4.1 (SEQ ID NO:252).

### Claim 31 (depends on 30)

The method of claim 30, wherein the composition comprising a nucleic acid encoding a recombinant HIV-1 envelope polypeptide comprising all the consecutive amino acids after the signal peptide in HIV-1 envelope CH505TFchim.6R.SOSIP.664v4.1 (SEQ ID NO:260).

### Claim 32 (depends on 30)

The method of claim 30, wherein the composition further comprises a carrier.

### Claim 33 (depends on 32)

The method of claim 32, further comprising administering an adjuvant.

### Claim 34 (depends on 30)

The method of claim 30, further comprising administering a recombinant HIV-1 envelope polypeptide comprising all the consecutive amino acids after the signal peptide in HIV-1 envelope CH505TFchim.6R.SOSIP.664v4.1 (SEQ ID NO:260).

### Claim 35

A method of inducing an immune response in a subject comprising administering a composition comprising any suitable form of a nucleic acid(s) encoding an HIV-I envelope(s) in an amount sufficient to induce an immune response from:
envelopes M5, M11, w20.14, w30.20, w30.12, and w136.B18 (Selection F, e.g. listed in FIG. 18A) or any combination thereof
and wherein the administration step can alternatively, or in addition, comprise administering an HIV-1 polypeptide(s) in an amount sufficient to induce an immune response from: envelopes M5, M11, w20.14, w30.20, w30.12, and w136.B18 (Selection F, e.g. listed in FIG. 18A) or any combination thereof.